| Document |
Document Title |
|
WO/2023/178299A1 |
This disclosure relates to ganaxolone derivatives, as well as methods of using the compounds (e.g., for treatment of a disease or disorder), methods of making the compounds, and pharmaceutical compositions and kits comprising the same.
|
|
WO/2023/168974A1 |
A cholic acid derivative, a preparation method therefor, and an application thereof as a TGR5 allosteric agonist. using CA as a lead compound, modification is performed at positions 7, 12, and 24 thereof by means of a series of reactions...
|
|
WO/2023/159094A2 |
The present disclosure relates to processes for preparing 3α-hydroxy-3β-methoxymethyl-21-(1'-imidazolyl)-5α-pregnan
-20-one and pharmaceutically acceptable salts thereof. The present disclosure further relates to purified 3α-hydroxy-...
|
|
WO/2023/155846A1 |
The present invention relates to a 17-pyridyl-10α-methyl-steroid derivative and intermediate compound, a preparation method therefor, a use thereof, and a pharmaceutical composition thereof. A methyl group at a C-10 position of the ster...
|
|
WO/2023/144782A1 |
A pharmaceutical composition comprising a compound shown in formula (I) or a pharmaceutically acceptable salt thereof, a cyclodextrin, and optionally, a buffer. Additionally provided are a preparation method for the pharmaceutical compos...
|
|
WO/2023/137529A1 |
The present invention relates to compounds which are active against parasitic infections, such as protozoan parasite infections (including flagellate parasite infections, ciliate parasite infections, amoeba parasite infections and apicom...
|
|
WO/2023/131310A1 |
Disclosed in the present invention are a steroid compound, and a preparation method therefor and the use thereof. The structure of the steroid compound is as shown in formula I, and the definition of each substituent in the formula are a...
|
|
WO/2023/105494A1 |
The present invention relates to cationic steroid compounds of formula (I) and methods of obtaining them. The present invention further relates to the incorporation of such compounds in a polymeric matrix composition or a coating composi...
|
|
WO/2023/079362A1 |
Provided herein are compounds having the formula D1-L-D2, wherein D1 is a processable group, L is a linker, and D2 is a drug. Also described herein are pharmaceutical compositions comprising said compounds and methods for the treatment o...
|
|
WO/2023/076605A1 |
The present invention relates to lipid amine compounds of formula (A1) which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/076598A1 |
Provided are lipid amine compounds which are useful in the preparation of lipid nanoparticle compositions for delivery of therapeutic or prophylactic payload into cells.
|
|
WO/2023/059581A1 |
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...
|
|
WO/2023/025241A1 |
Disclosed are a novel precursor compound of abiraterone, and a preparation method therefor and a use thereof. The structure of the compound is shown in formula I. The present invention also provides a preparation method for the compound ...
|
|
WO/2023/020135A1 |
Disclosed in the present invention are an abiraterone derivative and a preparation method therefor. The abiraterone derivative provided by the present invention shows relatively few abdominal distension phenomena with respect to abirater...
|
|
WO/2023/011513A1 |
A following compound or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotope labeled-compound, metabolite, chelate, complex, clathrate, or prodrug thereof, and a pharmaceutical com...
|
|
WO/2023/008891A1 |
The present invention relates to a novel compound and a preparation method therefor. The compound according to the present invention exhibits inhibitory activity against the generation of TNF-α that is an inflammatory cytokine produced ...
|
|
WO/2023/009584A1 |
This invention relates to crystalline forms of anhydrous Compound (1) and pharmaceutical compositions thereof. Also disclosed herein are methods of making crystalline solid forms of Compound (1), and methods of using the crystalline form...
|
|
WO/2022/264975A1 |
The present invention addresses the problem of providing a method for efficiently producing α-tomatine. The method for producing α-tomatine that solves the problem includes a step for mixing at least one tomato plant body selected from...
|
|
WO/2022/251588A1 |
The invention provides heterobifunctional compounds, pharmaceutical compositions and their use in protein degradation and treating disease, such as cancer. The heterobifunctional compounds feature thalidomide derived moieties that binds ...
|
|
WO/2022/246907A1 |
Provided are a compound containing a 2,4-thiazole ring, a preparation method therefor, and an application thereof. The compound is represented by formula (X), where A is pyrazolopyrimidine or indole; Z is absent or is a carbonyl group; X...
|
|
WO/2022/232104A1 |
The disclosure relates to methods of treating depression, pain, a musculoskeletal disorder or a motor disorder such as essential tremor with Compound 1 or pharmaceutically acceptable salts thereof.
|
|
WO/2022/232602A1 |
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases. These compounds are conjugates of glucocorticoids with rho-kinase inhibitors. Also provided herein are methods of t...
|
|
WO/2022/199408A1 |
Disclosed in the present invention are a novel injection polyaminopolycarboxylic acid-modified abiraterone derivative for treatment of prostate tumor, a pharmaceutical preparation containing the polyaminopolycarboxylic acid-modified abir...
|
|
WO/2022/196858A1 |
The present invention relates to a novel amino acid derivative, a preparation method therefor, and a pharmaceutical composition for treating hepatitis B or D, comprising same. A compound represented by chemical formula 1, according to th...
|
|
WO/2022/191092A1 |
The present invention addresses the problem of providing a new method for increasing the intracerebral histamine concentration. The present invention provides a compound represented by general formula (I) or a salt thereof. [In the formu...
|
|
WO/2022/178000A1 |
Disclosed herein are hemi-citrate salts of Compound (1), crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof, and methods of their use.
|
|
WO/2022/115381A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein ring D and the substituents are defined herein. Also provided are pharmaceutical compositions comprising a compound of Formula (I) or a p...
|
|
WO/2022/084752A1 |
The present invention relates to a process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione (VI) having the formula below: Compound (VI) can be used as a precursor for the synthesis of Clascoterone, a steroi...
|
|
WO/2022/078483A1 |
A quaternary ammonium steroid compound represented by formula I, or an addition salt or a solvate of the quaternary ammonium steroid compound: wherein R 1 is H or CH 3CO; R 2 is CH 3 or -CH 2CH＝CH 2, and t is equal to 2 or 3; X is Cl, ...
|
|
WO/2022/040545A1 |
The invention relates to particular substituted (3α,5β)-3-hydroxy-pregnan-20-ones, in free or pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use ...
|
|
WO/2022/022623A1 |
The present invention belongs to the technical field of medicine, and particularly relates to an arenobufagin derivative, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof. The arenobufagin derivati...
|
|
WO/2022/022559A1 |
The present disclosure relates to compounds which exhibit activity in the inhibition of platelet aggregation as well as pharmaceutical compositions comprising these compounds and methods of treatment of vascular diseases by administratio...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/236953A1 |
Cationic steroidal antimicrobial (CSA) compounds having a structure of Formula I, II or III, or salt thereof, wherein at least one of R1-R18, (e.g., R18) includes a terpenyl group attached via an ester or amide linkage and at least one R...
|
|
WO/2021/226465A1 |
The present disclosure relates to polycyclic (e.g., tetracyclic) glucocorticoid receptor (GR) modulators, synthetic methods for preparing such GR modulators, and methods of using such GR modulators to treat a glucocorticoid-dependent con...
|
|
WO/2021/217036A1 |
A molecule comprising a G-protein coupled estrogen receptor (GPER) ligand coupled to a linker coupled to an E3 ubiquitin ligase ligand and methods of using the molecule are provided. In one embodiment, the GPER ligand is estradiol and th...
|
|
WO/2021/188778A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R 4a, R4b, R5, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R18, R19, R20a, R20b, X, A, Z, q, u, r, s, t, m, and n are de...
|
|
WO/2021/179512A1 |
The present invention "an anti-influenza virus compound, and a preparation method therefor and an application thereof" relates to the technical field of pharmaceutical chemistry. The anti-influenza virus compound has the following struct...
|
|
WO/2021/147123A1 |
The present invention provides a compound having antisporulant activity and a pharmaceutical composition thereof, and specifically provides a compound represented by formula (I), or a salt thereof, or a stereoisomer thereof. The compound...
|
|
WO/2020/147852A9 |
The present application relates to crystal form 04, crystal form 06, crystal form D-1, and crystal form D-2 of an antidepressant drug SAGE-217 and a preparation method therefor and a pharmaceutical composition containing same. The XRPD o...
|
|
WO/2021/145785A1 |
Proposed are different benzimidazole derivatives based on thermolabile compounds, for example amino acids and vitamins, which exhibit geroprotective activity in trials and can be used for developing agents for prolonging life in humans a...
|
|
WO/2021/126281A1 |
Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit t...
|
|
WO/2021/113068A1 |
The invention provides novel neuroactive steroids and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, for example, various neurological or brain diseases.
|
|
WO/2021/100019A1 |
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers, or pharmaceutically acceptable salt(s) thereof as prodrugs of abiraterone. The present invention also describes method of makin...
|
|
WO/2021/096542A1 |
Formulated and/or co-formulated liposomes comprising IDO prodrugs and methods of making the liposomes are disclosed herein. The IDO prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit IDO-1. The IDO...
|
|
WO/2021/097046A1 |
The disclosure relates to anti-cancer compounds which are anti-cancer PARP inhibitors of formula Al, A2, A3 or A4 conjugated by a linker to a steroid, whereby the steroid targets the conjugate to the nucleus, as well as to methods for th...
|
|
WO/2021/082882A1 |
Disclosed is a method for anchoring and modifying a nano-drug on the surface of a living cell. The method comprises: introducing an active reaction group to the surface of a living cell by means of a hydrophobic tail chain of a cell memb...
|
|
WO/2021/080880A1 |
N-methyl-d-aspartate receptors (NMDAR) and/or potentiating y-aminobutyric acid receptors (GABAAR) agents and uses thereof are described. Uses of these agents include methods of treating or preventing various psychiatric diseases, disorde...
|
|
WO/2021/069570A1 |
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...
|
